RayKnowChina Research Map
Shortlist0

Not yet recruitingNasopharyngeal carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma

An open trial on nasopharyngeal carcinoma, registered on ClinicalTrials.gov. Led by Sun Yat-sen University Cancer Center; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Sun Yat-sen University Cancer Center中山大学肿瘤防治中心GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07902713, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 70 years; sex: all

    Registered eligibility fields

  2. At least one measurable lesion according to RECIST version 1.1. Previously irradiated lesions cannot be selected as target lesions unless unequivocal progression has been documented at least 3 months after the last radiotherapy.

    Inclusion criterion 5

    History of another malignancy unless the patient has received potentially curative treatment and remained recurrence-free for at least 5 years. Exceptions include adequately treated basal cell carcinoma of the skin, superficial bladder cancer, cutaneous squamous cell carcinoma, carcinoma in situ, and papillary thyroid carcinoma.

    Exclusion criterion 20

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    Inclusion criterion 6

  4. Hemoglobin ≥90 g/L;

    Inclusion criterion 8

    Platelet count ≥100 × 10⁹/L.

    Inclusion criterion 10

    Total bilirubin <2.0 × upper limit of normal (ULN);

    Inclusion criterion 12

    AST and ALT ≤2.5 × ULN in patients without liver metastases, or ≤3.0 × ULN in patients with liver metastases;

    Inclusion criterion 13

    Alkaline phosphatase ≤1.5 × ULN, or ≤2.0 × ULN in patients with liver metastases;

    Inclusion criterion 14

    Known hypersensitivity to any component or excipient of becotatug vedotin, including citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80; or a history of grade ≥3 hypersensitivity reactions to other anti-EGFR agents or monoclonal antibodies.

    Exclusion criterion 23

  5. Hepatitis B surface antigen (HBsAg) positivity with HBV DNA ≥500 IU/mL;

    Exclusion criterion 25

    Hepatitis C antibody positivity with detectable HCV RNA above the lower limit of detection.

    Exclusion criterion 26

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; scans and measurable lesions; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07902713, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Voluntary participation in the study and provision of written informed consent.
  • Male or nonpregnant female patients aged 18-70 years.
  • Life expectancy of at least 3 months.
  • Histologically or cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma (NPC) with treatment failure following prior platinum-based chemotherapy or PD-(L)1 inhibitor therapy. The two treatment modalities may have been administered concurrently as part of a first-line regimen or sequentially. Patients must be considered unsuitable for curative local salvage treatment, including surgery, re-irradiation, or other definitive local therapies.
  • At least one measurable lesion according to RECIST version 1.1. Previously irradiated lesions cannot be selected as target lesions unless unequivocal progression has been documented at least 3 months after the last radiotherapy.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Adequate hematologic function, defined as:
  • Hemoglobin ≥90 g/L;
  • White blood cell count ≥4.0 × 10⁹/L;
  • Platelet count ≥100 × 10⁹/L.
  • Adequate hepatic function, defined as:
  • Total bilirubin <2.0 × upper limit of normal (ULN);
  • AST and ALT ≤2.5 × ULN in patients without liver metastases, or ≤3.0 × ULN in patients with liver metastases;
  • Alkaline phosphatase ≤1.5 × ULN, or ≤2.0 × ULN in patients with liver metastases;
  • Serum albumin ≥30 g/L.
  • Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT), and activated partial thromboplastin time (APTT) ≤1.5 × ULN. Patients receiving anticoagulant therapy are eligible if their anticoagulation parameters are within the therapeutic range and are closely monitored by the investigator.
  • Adequate renal function, defined as serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min calculated using the adjusted Cockcroft-Gault formula if serum creatinine exceeds 1.5 × ULN.
  • Women of childbearing potential and male patients of reproductive potential must agree to use adequate contraception throughout study treatment and for 180 days after the last dose of study treatment.

Exclusion Criteria:

  • Histologically confirmed keratinizing squamous cell carcinoma (WHO type I).
  • Grade ≥2 peripheral neuropathy according to CTCAE version 5.0.
  • Anticipated requirement for surgery or any other systemic or local anticancer therapy during the study, including palliative treatment, except for palliative treatment directed at non-target lesions.
  • Receipt of any of the following treatments before the first dose of study treatment:
  • Systemic chemotherapy within 3 weeks;
  • Small-molecule targeted therapy within 2 weeks or 5 half-lives, whichever is longer;
  • Anticancer biological therapy, macromolecular targeted therapy, or immunotherapy within 4 weeks;
  • Major surgery within 4 weeks, except for minor surgery performed within 2 weeks with complete recovery;
  • Radiotherapy within 14 days, or radiotherapy to the central nervous system within 28 days.
  • Known active central nervous system (CNS) metastases or carcinomatous meningitis. Patients with previously treated brain metastases may be eligible if clinically stable, without progressive or new neurological deficits, seizures, evidence of increased intracranial pressure, vomiting, or headache, and without evidence of lesion enlargement on MRI during the preceding 4 weeks or a requirement for corticosteroids during the 14 days before the first dose of study treatment.
  • Residual toxicities from previous anticancer treatment, including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, or clinically significant laboratory abnormalities greater than grade 1 according to CTCAE version 5.0, except for alopecia, fatigue, and grade 2 hypothyroidism.
  • Uncontrolled or poorly controlled cardiovascular disease, including any of the following:
  • Grade ≥2 congestive heart failure within 6 months before enrollment;
  • Myocardial infarction or unstable angina;
  • History of ventricular tachycardia or torsades de pointes;
  • Clinically significant arrhythmias requiring treatment;
  • QTcF >450 ms in males or >470 ms in females;
  • Complete left bundle branch block or third-degree atrioventricular block.
  • Pulmonary embolism or deep vein thrombosis within 3 months before the first dose of study treatment, except for thrombosis associated with an implanted venous port or peripherally inserted central catheter (PICC).
  • History of another malignancy unless the patient has received potentially curative treatment and remained recurrence-free for at least 5 years. Exceptions include adequately treated basal cell carcinoma of the skin, superficial bladder cancer, cutaneous squamous cell carcinoma, carcinoma in situ, and papillary thyroid carcinoma.
  • Any severe or uncontrolled systemic disease, including poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) or poorly controlled diabetes mellitus (HbA1c >8%).
  • Active bleeding, history of a bleeding or coagulation disorder, or current treatment with coumarin anticoagulants.
  • Known hypersensitivity to any component or excipient of becotatug vedotin, including citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80; or a history of grade ≥3 hypersensitivity reactions to other anti-EGFR agents or monoclonal antibodies.
  • Active hepatitis B or hepatitis C infection, defined as:
  • Hepatitis B surface antigen (HBsAg) positivity with HBV DNA ≥500 IU/mL;
  • Hepatitis C antibody positivity with detectable HCV RNA above the lower limit of detection.

Patients with other severe liver diseases, including chronic autoimmune liver disease, primary biliary cirrhosis, sclerosing cholangitis, alcoholic liver disease, or nonalcoholic steatohepatitis (NASH), will also be excluded.

  • Severe uncontrolled infection, known HIV infection, or acquired immunodeficiency syndrome (AIDS); active autoimmune disease, except for type 1 diabetes mellitus, hypothyroidism controlled with replacement therapy, or skin disorders not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia); or a history of allogeneic tissue or organ transplantation, stem cell transplantation, or bone marrow transplantation.
  • Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring systemic antimicrobial treatment, unless adequately treated and resolved before the first dose of study treatment.
  • Receipt of a live-virus vaccine within 30 days before the first dose of study treatment.
  • History of or concurrent interstitial pneumonitis, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary dysfunction, or symptomatic bronchospasm.
  • Receipt of immunologically based treatment for any reason, including chronic systemic corticosteroid therapy equivalent to >10 mg/day of prednisone within 7 days before the first dose of study treatment or during study participation. Inhaled or topical corticosteroids, systemic corticosteroids equivalent to ≤10 mg/day of prednisone, and short-term corticosteroid use at higher doses for specific indications (such as premedication before contrast administration) are permitted.
  • Uncontrolled pleural, abdominal, pelvic, or pericardial effusion requiring drainage at least once per month.
  • Positive pregnancy test, current breastfeeding, or unwillingness to use adequate contraception during study treatment and for 180 days after the last dose of study treatment.
  • Any other disease, clinically significant laboratory abnormality, serious medical or psychiatric condition, or substance abuse (including alcohol abuse) that, in the investigator's judgment, may compromise patient safety, study integrity, study participation, or interpretation of study results.

Quoted from ClinicalTrials.gov, NCT07902713, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07902713, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07902713